Multiple receptor conversions during the course of metastatic breast cancer therapy: a case report and review of the literature

Autor: Yolcar Chamorro, Ana C. Sandoval-Leon, Charles L. Vogel, Michaela T. Nguyen, Grace Wang

Publikováno v: Journal of Medical Case Reports, Vol 16, Iss 1, Pp 1-6 (2022)

Abstract Background Adjuvant systemic therapy decreases recurrence and death from breast cancer, but late relapse still occurs. Therapeutic decisions are based heavily on receptor tissue characterization. Even though the vast majority of metastatic s

Externí odkaz: https://doaj.org/article/9ed025a8b89749d4918e288d56d3b8bd

Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer

Autor: Charles L, Vogel, Melody A, Cobleigh, Debu, Tripathy, John C, Gutheil, Lyndsay N, Harris, Louis, Fehrenbacher, Dennis J, Slamon, Maureen, Murphy, William F, Novotny, Michael, Burchmore, Steven, Shak, Stanford J, Stewart, Michael, Press

Publikováno v: Journal of Clinical Oncology. 41:1638-1645

PURPOSE To evaluate the efficacy and safety of first-line, single-agent trastuzumab in women with HER2-overexpressing metastatic breast cancer. PATIENTS AND METHODS One hundred fourteen women with HER2-overexpressing metastatic breast cancer were ran

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbad728710b584bef814c355e69a2d35
https://doi.org/10.1200/jco.22.02516

A Roundtable Discussion of the Breast Cancer Therapy Expert Group (BCTEG): Clinical Developments and Practice Guidance on Human Epidermal Growth Factor Receptor 2 (HER2)-positive Breast Cancer

Autor: Muaiad Kittaneh, Hope S. Rugo, Charles L. Vogel, Michael F. Press, Sunil Badve, Elyse E. Lower, Mark D. Pegram, Reshma Mahtani, Kevin Kalinsky, Eleftherios P. Mamounas, Robert E. Coleman, Lee S. Schwartzberg, Frankie-Ann Holmes, Humberto Caldera

Publikováno v: Clinical Breast Cancer. 20:e251-e260

Expression of human epidermal growth factor receptor 2 (HER2) in breast cancer defines a subset of patients (∼15%-20%) who are candidates for anti-HER2 therapies, most notably, trastuzumab, pertuzumab, antibody drug conjugates (eg, T-DM1), and tyro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2b73fca648c1206827d45755882cbcb
https://doi.org/10.1016/j.clbc.2019.08.001

Testing a positive-affect induction to reduce verbally induced nocebo hyperalgesia in an experimental pain paradigm

Autor: Lene Vase, Yopina G. Pertiwi, Fawn C. Caplandies, Ashley B. Murray, Andrew L. Geers, Ian M. Handley, Shane Close, Charles L Vogel

Publikováno v: Geers, A L, Close, S, Caplandies, F C, Vogel, C L, Murray, A B, Pertiwi, Y, Handley, I M & Vase, L 2019, ' Testing a positive-affect induction to reduce verbally induced nocebo hyperalgesia in an experimental pain paradigm ', Pain, vol. 160, no. 10, pp. 2290-2297 . https://doi.org/10.1097/j.pain.0000000000001618

There is an ethical obligation to notify individuals about potential pain associated with diagnoses, treatments, and procedures; however, supplying this information risks inducing nocebo hyperalgesia. Currently, there are few empirically derived stra

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::deaa03049d2c35763775b65df099b46e
https://doi.org/10.1097/j.pain.0000000000001618

Phase 3 ENABLAR-2 study to evaluate enobosarm and abemaciclib combination compared to estrogen-blocking agent for the second-line treatment of AR+, ER+, HER2- metastatic breast cancer in patients who previously received palbociclib and estrogen-blocking agent combination therapy

Autor: Elgene Lim, Adam Brufsky, Hope S. Rugo, Charles L. Vogel, Joyce O'Shaughnessy, Robert H. Getzenberg, K. Gary Barnette, Domingo Rodriguez, Gary Bird, Mitchell S. Steiner, Hannah M. Linden

Publikováno v: Journal of Clinical Oncology. 40:TPS1121-TPS1121

TPS1121 Background: Targeting the androgen receptor (AR) may be the next important endocrine therapy for advanced breast cancer. The AR has been demonstrated to be a tumor suppressor when activated. Enobosarm is an oral selective AR targeting agonist

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::019e30b53b65e2baa934921348672843
https://doi.org/10.1200/jco.2022.40.16_suppl.tps1121